Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
3,635 total articles
Delek US Holdings President and CEO Avigal Soreq sold 50,000 shares on March 3, 2026, generating roughly $2.05 million in proceeds through three transactions executed under a 10b5-1 plan. The stock has climbed sharply over the past year and is trading near its 52-week high, while independent analysis flags the shares as overvalued versus Fair Value…
Kevin Maddock, Executive Vice President at Rimini Street (NASDAQ: RMNI), sold 2,809 shares on March 3, 2026, for a total of $10,445 to satisfy tax obligations tied to vesting restricted stock units. The company reported profitability over the trailing twelve months and trades at a P/E ratio of 9.53. Separately, Tidewater Inc. has broadened its use …
Corvex Management LP and director Keith A. Meister disclosed purchases of GeneDx Holdings Corp. (NASDAQ: WGS) Class A Common Stock totaling about $13.4 million. The transactions took place on March 3 and March 5, 2026, at prices between $70.34 and $82.06. The buying activity arrives after a 38% decline in the stock over the past six months and amid…
Adaptive Biotechnologies Corp executive Julie Rubinstein sold 92,823 shares of common stock for roughly $1.49 million between March 3 and March 5, 2026, and exercised options to acquire 73,610 shares at $6.55 and $12.14. The stock is trading at $15.93, up 105% over the past year; InvestingPro analysis notes possible overvaluation versus its Fair Va…
Halide Alagoz, Chief Product & Merchandising Officer at Ralph Lauren Corp (NYSE:RL), sold 1,120 shares of Class A Common Stock on March 4, 2026, for $362.00 per share, totaling $405,440, according to a Form 4 filed with the SEC. After the transaction Alagoz holds 21,113 shares directly. The filing notes the sale was part of a long-term plan for est…
John W. Schlosser, Vice President and President, Terminals at Kinder Morgan, sold 6,166 shares of Class P common stock on March 5, 2026, for about $207,640 under a 10b5-1 trading plan. The stock has risen roughly 28% over six months and is trading close to its 52-week high. Multiple analysts reconfirmed or raised targets after Kinder Morgan's stron…
Rimini Street Executive Vice President and Chief Marketing Officer David W. Rowe exercised 6,667 options with a zero exercise price and sold 2,809 shares on March 3, 2026, in a transaction automatically triggered to meet tax-withholding obligations. After the transactions Rowe directly holds 457,789 shares. Rimini Street shares trade below Investin…
LeonaBio President and CEO Mark James Litton reported a sale of 5,156 shares on March 4, 2026, raising $27,687 at a weighted-average price of $5.37 per share after exercising options the prior day. The transaction comes amid corporate restructuring, a major licensing deal for lasofoxifene and fresh financing and analyst coverage that have shaped ma…
Beta Bionics NASDAQ:BBNX Chief Commercial Officer Hopman Mark sold 353 shares on March 4, 2026, at $11.57 per share for about $4,084. The transaction was executed under a Rule 10b5-1 plan adopted May 13, 2025, and was disclosed in a Form 4 filing. The stock has fallen 12% over the past week and is down 64% year-to-date. Analysts continue to offer d…
Timothy R. Barakett, a director at KKR & Co. Inc., purchased 50,000 shares of common stock on March 4, 2026, for roughly $4.72 million. The trade comes amid a quarter in which KKR missed consensus adjusted EPS and as the firm pursues potential disposals and strategic partnerships, including a possible sale of BMC Helix and talks about a renewable-e…
Stephen L. Rohde, a director at Slide Insurance Holdings, Inc. (NYSE: SLDE), sold 10,000 shares across March 3 and March 4, 2026, for about $193,300 and simultaneously exercised options to buy 10,000 shares for $0.0018 each. The transactions occurred as SLDE stock has risen 42% over six months and after the company reported a sizable fourth-quarter…
Voss Capital and affiliated vehicles purchased $14.6 million of PAR Technology (NASDAQ: PAR) shares between January 14 and February 4, 2026, paying between $22.1999 and $39.1047 per share. The trades increased Voss-linked direct holdings and included several call option purchases. The activity comes as PAR shares trade at $19.52, down 68% over the …
Matthew Paul Larson, Chief Risk Officer of Slide Insurance Holdings Inc. (NASDAQ:SLDE), sold 11,250 shares on March 3, 2026, for roughly $213,862 and concurrently exercised options on 11,250 shares at $0.79 per share. The moves were disclosed in a Form 4 filing and occur amid solid quarterly results and valuation metrics showing SLDE trading at a P…
Castle Biosciences Inc (NASDAQ:CSTL) Chief Financial Officer Frank Stokes sold 7,000 shares on March 3, 2026, in two tranches that generated roughly $192,073. Around the same time he sold additional shares to cover taxes and exercised options to acquire nearly 28,000 shares while receiving 48,367 restricted stock units. The activity coincides with …
LeonaBio, Inc. (NASDAQ: LONA) reported a modest insider sale by Chief Financial Officer Robert Renninger tied to taxes on vested restricted stock units, alongside disclosures that include option exercises and a remaining direct holding of 15,851 shares. The company is navigating a strategic pivot toward oncology with licensed global rights for laso…
Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (BCAX), sold 17,392 shares on March 3, 2026, for about $315,892 and concurrently exercised options to acquire 12,892 shares. The transactions were carried out under a Rule 10b5-1 plan adopted February 12, 2025. Bicara has recently completed a large stock offering and received an analyst r…
Intuitive Surgical's SVP and head of manufacturing and supply chain, Brosius Mark, sold 3,658 shares of company stock in three transactions between March 3 and March 5, 2026, for a total of $1,815,061. The disposals were carried out under a Rule 10b5-1 trading plan set to expire February 14, 2027. Separately, the company reported robust fourth-quar…
Northern Trust Executive Vice President and Chief Financial Officer David W. Fox Jr. sold 3,255 shares on March 4, 2026, for $468,361. The transaction comes as the company reported stronger fourth-quarter 2025 results and multiple brokerages raised price targets. Fox's remaining direct and indirect holdings are detailed in a Form 4 filing.
Director Richard W. Fisher sold 16,345 shares of Warner Bros. Discovery (WBD) Series A common stock on March 3, 2026, generating about $462,726. The sale occurred as the stock has seen significant recent gains but is flagged as overvalued by InvestingPro. The transaction takes place against a backdrop of merger and deal activity, including Paramoun…
Will W Anthony, formerly president and CEO of CF Industries, sold 64,273 shares of common stock on March 3, 2026, in two transactions totaling about $7,009,894. After the sales Anthony retains direct ownership of 194,010 shares. The trades come while CF Industries shares trade near a 52-week high and after the company reported robust fourth-quarter…
SFS Holding Corp., an entity through which Mat Ishbia indirectly holds shares, sold 1,898,622 Class A shares of UWM Holdings Corp (NASDAQ: UWMC) across three transactions from March 3-5, 2026, generating roughly $7.9 million in proceeds. The trades were executed under a 10b5-1 plan adopted in September 2025. The sales occur against a backdrop of re…
NPEH, LLC, a 10% holder of NET Power Inc. (NYSE: NPWR), disposed of 100,000 Class A shares on March 3, 2026, receiving $204,250 for the stock sold at prices between $2.01 and $2.015. The transaction leaves NPEH with 400,000 directly held shares. NET Power has fallen roughly 70% over the past year and is trading near a 52-week low of $1.48; earnings…
Joseph Loscalzo, a member of Ionis Pharmaceuticals' board, sold 1,032 shares in early March 2026 for roughly $82,832 and simultaneously exercised options to acquire the same number of shares at $38.06. The transactions coincide with a flurry of regulatory and clinical activity at the biotech, including an FDA acceptance of a supplemental NDA for ol…
Ionis Pharmaceuticals director Joseph Klein III sold 21,332 shares on March 3, 2026 for roughly $1.7 million, with transaction prices between $79.174 and $80.818. He also exercised options to acquire 16,000 shares at strike prices of $40.05 and $42.88, valued at $652,120. After the trades, Klein owns 11,014 shares directly and his son holds 100 sha…
Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals, sold 20,006 shares on March 3, 2026, for about $1.59 million after exercising options to acquire the same number of shares. The company recently secured FDA Priority Review for olezarsen with a target action date of June 30, 2026, and will presen…
